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Suvruanv
Acute myeloid leukemia (AML) is a malignant clonal disorder, characterized by the
accumulation of an immature cell population in the bone marrow. The expansion of the
leukemic clone eventually results in suppression of the normal hematopoiesis. Treatment
with intensive chemotherapy is the only option to eliminate the malignant cells from the
bone marrow. Although many patients achieve a complete remission after intensive
chemotherapy, a number of patients are refractory to this treatment, and a large
proportion of the patients shows a relapse after having reached complete remission,
illustrating treatment failure. Different prognostic factors have been defined that are
predictive for treatment outcome in AML]. Low white blood cell counts, structural
abnormal i t ies in  karyotype,  such as invers ion(16) ,  t ranslocat ions(16;16) ,  (15;17)  and
(8;2 1), are important factors determining good response. Other factors, including high
white blood cell counts, immature immunophenotype, increasing age, structural
karyotypic abnormalities such as a deletion of chromosome 5 or 7, and an internal
tandem duplication of the Ftt3 gene on chromosome l3 2'3, are assoclated with a worse
outcome in AML.
In addition, treatment faiiure in AML is associated with the presence of intrinsic or
acquired resistance to chemotherapeutic agents. One type of drug resistance mechanisms
is characterized by the resistance to several structurally and functionally unrelated drugs,
and is called multidrug resistance (MDR). The overexpression of adenosine triphosphate
(ATPt-dependent  membrane t ransporter  prote ins.  which funct ion as drug ef f lux pumpsa.
has been identif ied as a MDR mechanism. Transfection and overexpression studies with
the genes encoding drug efflux pumps in human cell l ines have shown that these
transporter proteins confer resistance to a wide range of chemotherapeutic agents,
including daunorubicin, doxorubicin, mitoxantrone and etoposide, which are drugs used
in the treatment of patients with AML.
The studies described in this thesis are focused on the role of the drug efflux pumps P-
glycoprotein (P-gp), encoded by the MDR| gene, the multidrug resistance protein 1
(MRPI) and its homologues, especially MRP2, MRP3, MRP5 and MRP6, and the novel
breast cancer esistance protein (BCRP)5, in AML.
In chapter I an overview is given ofthe current knowledge concerning these transporter
proteins, with emphasis on the expression and especially the functional activity of the
drug efflux pumps in AML cells. P-gp has been shown to be associated with poor
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treatment outcome in AML patients. Besides P-gp, MRPl appeared to contribute to the
observed resistance in AML. MRP2, MRP3, MRP5, MRP6 and BCRP, have been shown
to be expressed at variable levels in AML patient cells. The latter proteins have been
described to confer resistance to chemotherapeutic drugs such as daunorubicin,
mitoxantrone, etoposide and 6-mercaptopurine, which are generally used in the treatment
of AML patients; however, they have not yet proven to play a role in drug resistance in
AML.
Chapter 2 describes the development of a functional assay to measure the activity of
MRPl. The fluorescent compound carboxyfluorescein, which is formed after cleavage of
the non-fluorescent carboxyfluorescein diacetate by intracellular esterases, and which is
transported by MRPI, was used in a flow cytometric assay. In addition it was shown that
the transport of carboxyfluorescein could be inhibited by the leukotriene D4 receptor
antagonist MK-571 Ín several MRPl overexpressing cell l ines. Subsequently, the MRP
activity was measured in 15 AML samples, and appeared to vary widely between the
cases. The MRP activity correlated positively with MRPI protein expression. Besides
MRPI protein expression, mRNA transcripts of the MRPI homologue MRP2 were
demonstrated in 40%o f the AML cases.
In this study 2 patients with inversion of chromosome 16, on which MRPl is located,
were included. These patients showed a low MRP activity, possibly reflecting the
dysfunction of the MRPI pump as result of the chromosomal inversion. This stimulated
the study in chapter 3, where we focussed on AML patients with inversion(16). In a
paper by Kuss el a/.u, it has been reported that a deletion of one MRPt allele in patients
with inversion(16) was associated with a prolonged duration of disease fiee survival,
suggesting an important role for MRPI in determining clinical outcome. That study did
not evaluate the MRP activity in this patient group. We therefore analyzed MRP I
deletion by fluorescenï in situ hybridization (FISH), with a focus on inversion(16)
patients, and found a deletion of I or 2 MRPI alleles in 7 out of I I patient samples. The
occurrence of these deletions correlated with low MRP activity. However, the MRP
activity in the AML cases was not different from that in normal hematopoietic ells.
Furthermore, the mRNA expression of MDRI, MRPI, MRP2 and MRP6 were
determined, and MRP2 and MRP6 mRNA appeared to be predominantly expressed in
AML samples with I MRPI allele, whereas in normal bone marrow cells no MRP2 and
MRP6 mRNA was observed. In addition, P-gp activity was observed in a patient sample
which showed no MRP activity and no expression of MRP mRNA transcripts. In
conclusion, these findings demonstrate that in AML patients with inversion(16) no
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distinct difference in MRP activity can be observed compared to normal hematopoietic
cells, despite the deletion of 1 or 2 MRP| alleles. This could in part be due to the
upregulation of other MDR genes. Therefore, the favorable prognosis of inversion(16)
AML patients is not necessarily caused by the deletion of MRP L
In chapter 4 the role of P-gp and MRP activity on treatment outcome in 104 de n.ovo
AML patients was evaluated. P-gp and MRP activit ies were determined with a flow
cytometric assay, measuring rhodamine 123 accumulation with or without the P-gp
inhibitor PSC833, and carboxyfluorescein accumulation with or without the MRP
inhibitor MK-571, respectively. The results were compared with clinical outcome and
with known prognostic factors. A low rhodamine 123 accumulation and a high
rhodamine 123 efflux-blocking by PSC833 were associated with a low complete
remission rate after the first cycle of chemotherapy. Patients with both low rhodamÍne
123 and carboxyfluorescein accumulation had the lowest cornplete remission rate (60Á),
whereas patients with both high rhodamine 123 and carboxyfluorescein accumulation had
a high complete remission rate (73oÁ) after the first chemotherapy cycle. No correlations
were observed between the multidrug resistance parameters and overall survival of the
AML patients. The known high risk group, including cytogenetic aberrations uch as
deletions of chromosome 5 or l, and high white blood cell counts, was the only
predictive parameter for the poor overall survival.
In chapter 5, we investigated whether P-gp or MRP activity in AML patient samples
were upregulated at relapse or in rellactory disease, as a result of clonal selection. Clonal
selection might occur when drug resistant cell populations escape init ial treatment and
emerge after a certain period of t ime. In 30 paired samples of de novo and relapsed or
refractory AML, no consistent upregulation of P-gp nor MRP activity was observed at
relapse. P-gp activity was increased in20oÁ and decreased in35%o of the relapse samples,
while MRP activity was increased in35%o and decreased in l5%o of the relapse samples in
comparison to the de zlovo samples. Since it has been described that P-gp expression is
correlated with expression of the immature surface marker CD34, we also analyzed the
change in surface marker expression at relapse as compared with de novo AML cells. A
more mature phenotype was observed in20oÁ of the relapse cases, whereas in 25% of the
cases the relapsed blasts had become less mature than the de novo samples. P-gp and
MRP activity correlated with the phenotypic changes. Higher P-gp as well as MRP
activit ies were observed in the relapse samples that had become less mature as compared
with the primary samples. Lower P-gp and MRP activity were found when the relapse
sample demonstrated a more mature phenotype than the primary sample.
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A relatively new MDR protein is BCRP, also known as MXR, ABCP or ABCG2, a 655-
amino-acid protein, encoded by the BCRP gene located on chromosome 4q225.
Overexpression of BCRP has been observed in human cancer cell l ines selected for
resistance with mitoxantrone, doxorubicin plus verapamil, or topotecan.
In chapter 6, the expression and activity were analyzed of this novel MDR protein
BCRP, that might be involved in drug resistance in AML. Chemotherapeutic agents such
as mitoxantrone and daunorubicin, are flequently used in the treatment of these patients,
and have been described to be substrates for this drug efflux pump. In 20 paired cases of
de novo and relapsed or refractory AML, BCRP protein appeared to be expressed at low,
but variable levels. BCRP functional activity was studied by measuring the capacity of
the AML cells to extrude mitoxantrone in the nresence or absence of the BCRP inhibitor
fumitremorgin C.
Relatively high BCRP expression in the AML blasts was conelated with a low
mitoxantrone accumulation, even when the activity of P-gp and MRP were inhibited by
PSC833 and MK-571. Addition of the inhibitor fumitremorgin C showed an increase in
mitoxantrone accumulation only if combined with PSC833 or MK-571, in contrast o a
distinct effect of fumitremorgin C alone in a BCRP overexpressing cell l ine. No
consistent upregulation of BCRP protein expression or mitoxantrone accumulation was
observed in relapsed or reflactory AML samples as compared to primary cases; some
cases showed an increase, other cases a decrease of BCRP protein expression at relapse.
Since it has been described that BCRP is predominantly expressed in the most primitive
hematopoietic side population cells, we subsequently evaluated whether a similar pattern
could be observed in AML patient samples. Indeed, relatively high BCRP expression
correlated with an immature immunophenotype, as determined by CD34 expression . In
conclusion this study shows that BCRP protein is expressed at low, but variable levels in
AML cells, especially in the immature CD34* subpopulation. BCRP was not found to be
consistently upregulated in relapse or refractory AML, but was increased in the cases
with a less mature immunophenotype, and decreased in the cases with a more mature
immunophenotype at relapse. These findings, which were also observed for P-gp and
MRP, suggest a role for the transporter proteins in maintaining a primitive phenotype in
hematopoietic ells.
In conclusion, the studies presented in this thesis demonstrate that drug resistance in
AML, as conferred by the expression of drug efflux pumps, is a complex phenomenon.
An interplay appeared to exist between the different efflux pumps, in which a relatively
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high expression of the pumps in hematopoietic cells of the normal and malignant
counterpart was shown to be determined by an early maturation stage of the cells.
GENBnaL DISCUSSIoN
In addition to P-gp, which has been shown to be an independent poor prognostic factor of
c l in ica l  outcome in AML, MRP1, a l though to a lesser  extent ,  appeared to p lay a ro le in
MDR in AML. Legrand et ol. have reported that MRP activity, as determined by the
modulatory effect of the inhibitor probenecid on calcein efflux, is a poor prognostic
factor for the achievement of conrplete remission. Furlhermore, the simultaneous activity
of P-gp and MRP were correlated with poor clinical outcome t't. The latter f inding was
confirmed by our study in 104 de novo AML patients, in which patients with both low P-
gp and MRP activity had a complete remission rate of l30Á, whereas patients with both
high P-gp and MRP activity had a cornplete remission rate of 6Yo aft,er the first cycle of
chemotherapy. MRP activity was measured with an assay using carboxyfluorescein as a
substrate in cornbination with the MRP inhibitor and leukotriene D4 receptor antagonist
MK-571. Although the kinetic transport properties of MRPI and MRP2 are different e,
the substrate specificit ies of MRPl and MRP2 are largely similar. It is therefore
reasonable to assume that, besides MRPl, MRP2 effluxes carboxyfluorescein and that
MRP2 activity is also measured in this efflux assay. MRP3, in contrast o MRPI and
MRP2, has been shown to be a lorv-affinity transporter for glutathione conjugatesr0.
Since carboxyfluorescein is transported independently of glutathione ", it is probably
also ef f luxed by MRP3. I t  is  unl ike ly  that  MRP4 or  MRP5 act iv i ty  is  measured in the
used flow cytometric assay, since it has been reported that these proteins do not transporl
ler"rkotriene C4 12:r3 and that the leukotriene D4 receptor antagonist MK-571 does not
inhib i t  MRP5 mediated t Íanspof t ' r .  The other  MMI homologues,  and possib ly  some yet
unidentif ied MRPs, might contribute to the carboxyfluorescein efflux assay. For that
reason the assay most  l ike ly  measures an overal l  MRP act iv i ty ,  instead of  MRPI act iv i ty
specifically. However, we have observed a correlation between carboxyfluorescein
ef f lux-b lock ing by MK-571 and MRPI prote in expression 'u  and,  to  a lesser  extent  MRPl
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